Relief reports that its US collaborative partner announced improved one-year survival in highly comorbid COVID-19 patients treated with ZYESAMITM (RLF-100TM / aviptadil)

0


GENEVA, SWITZERLAND / ACCESSWIRE / September 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (“Relief“), a biopharmaceutical company seeking to provide patients with therapeutic relief from serious illnesses with high unmet needs, today announced that the parent company of its US collaborative partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP ) (“NRx“), issued a press release announcing first-line data demonstrating improved results at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI (TM) (RLF-100 (TM) / aviptadil According to the NRx press release, in highly comorbid COVID-19 patients, ZYESAMI (TM) provided a statistically significant increase in the probability of one-year survival by three, consistent, according to NRx, with the increased odds of 60-day survival observed in previously reported results of the phase 2b / 3 randomized controlled trial of ZYESAMI (TM) (RLF-100 (TM) / aviptadil). The related NRx press release can be accessed via the following link connect.

ABOUT RESCUE

Relief primarily focuses on clinical stage programs based on molecules with a history of clinical trials and use in human patients or strong scientific rationale. Relief’s lead drug candidate, RLF-100 (TM) (aviptadil), a synthetic form of vasoactive intestinal peptide (VIP), is in advanced clinical trials in the United States for the treatment of respiratory impairment due to COVID -19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a collaboration and license agreement with Acer Therapeutics for the global development and commercialization of ACER-001. ACER-001 is a patented, taste-masked, immediate-release powder formulation of sodium phenylbutyrate (NaPB) for the treatment of urea cycle disorders and maple syrup disease. In addition, Relief’s recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, provide Relief with a diverse portfolio of commercialized and development-phase programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and listed in the United States on the OTCQB under the symbol RLFTF. For more information visit www.relieftherapeutics.com. follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA
Jack weinstein
Financial Director and Treasurer
contact@relieftherapeutics.com

FOR MEDIA / INVESTOR REQUESTS:
Rx communication group
Michael miller
+ 1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG. These statements involve certain known and unknown risks, uncertainties, and other factors, including (i) whether aviptadil will be determined by regulatory authorities to be safe and effective as a treatment for highly co-morbid patients with COVID-19 , (ii) whether aviptadil will ever be approved in the US, UK or EU for the treatment of respiratory failure in patients with COVID-19 and (iii) the risks discussed in press releases and records of RELIEF THERAPEUTICS Holding AG with SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from the expressed future results, performance or achievements or implied by these forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

THE SOURCE: Relief Therapeutics Holdings AG

See the source version on accesswire.com:
https://www.accesswire.com/665849/Relief-Reports-that-its-US-Collaboration-Partner-has-Announced-Improved-Survival-at-One-Year-in-Highly-Comorbid-COVID-19- Patients-treated-with-ZYESAMITM-RLF-100TMaviptadil


Share.

Leave A Reply